The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Omnicom has won the U.S. media account for Novo Nordisk, the maker of Ozempic and Wegovy. While this is an advertising industry headline, it carries real implications for how GLP-1 medications are marketed and potentially priced. Here's what patients need to know.
Several major pharmacy chains now offer GLP-1 weight loss medications at dramatically reduced prices through discount programs. This guide breaks down which pharmacies participate, what's actually available at $50, and how to navigate the fine print so you're not caught off guard.
Amazon Pharmacy has launched a $50/month GLP-1 medication program for eligible Medicare patients, a significant shift in how older Americans can access semaglutide and similar drugs. This guide breaks down who qualifies, what's included, and how it compares to other access routes.
Bank of America's CEO recently revealed the company spends $250 million a year on GLP-1 medications for its employees. This signals a major shift in how large employers view these drugs, and it has real implications for patients trying to access and afford semaglutide or tirzepatide.
Eli Lilly's tirzepatide medications, Mounjaro and Zepbound, are pulling ahead of Novo Nordisk's semaglutide offerings in sales. For patients weighing their GLP-1 options, this shift carries real implications for access, pricing, and what to expect from your provider. Here's what you need to know.
Novo Nordisk raised its financial outlook, but investors weren't impressed after oral semaglutide sales came in below expectations. For patients researching GLP-1 medications, this news has real implications for access, pricing, and the future of weight loss treatment options.
South Korea is moving to classify Wegovy and Mounjaro as drugs with abuse potential, triggered by surging sales and off-label use for cosmetic weight loss. This regulatory shift reflects a growing global conversation about who should have access to GLP-1 medications and how they are prescribed. Here is what this development means for patients using or considering these drugs.
People taking GLP-1 medications like semaglutide and tirzepatide are reporting an unexpected new fixation: drinking water. Learn why this happens, what the science suggests, and how to make this quirky side effect work for your weight loss goals.
